Kari G Rabe

List of Publications by Citations

142 papers	4,691 citations	38 h-index	66 g-index
147 ext. papers	5,701 ext. citations	6 avg, IF	4.77 L-index

#	Paper	IF	Citations
142	Detectable clonal mosaicism and its relationship to aging and cancer. *Nature Genetics*, **2012**, 44, 651-8	36.3	409
141	Association Between Inherited Germline Mutations in Cancer Predisposition Genes and Risk of Pancreatic Cancer. *JAMA - Journal of the American Medical Association*, **2018**, 319, 2401-2409	27.4	222
140	Whole Genome Sequencing Defines the Genetic Heterogeneity of Familial Pancreatic Cancer. *Cancer Discovery*, **2016**, 6, 166-75	24.4	206
139	Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia. *Blood*, **2014**, 124, 49-62	2.2	202
138	BRCA1, BRCA2, PALB2, and CDKN2A mutations in familial pancreatic cancer: a PACGENE study. *Genetics in Medicine*, **2015**, 17, 569-77	8.1	175
137	Common variation at 2p13.3, 3q29, 7p13 and 17q25.1 associated with susceptibility to pancreatic cancer. *Nature Genetics*, **2015**, 47, 911-6	36.3	171
136	Probability of pancreatic cancer following diabetes: a population-based study. *Gastroenterology*, **2005**, 129, 504-11	13.3	167
135	Diffuse large B-cell lymphoma (Richter syndrome) in patients with chronic lymphocytic leukaemia (CLL): a cohort study of newly diagnosed patients. *British Journal of Haematology*, **2013**, 162, 774-82	4.5	151
134	Genome-wide association study identifies multiple risk loci for chronic lymphocytic leukemia. *Nature Genetics*, **2013**, 45, 868-76	36.3	147
133	Detection of early pancreatic ductal adenocarcinoma with thrombospondin-2 and CA19-9 blood markers. *Science Translational Medicine*, **2017**, 9,	17.5	137
132	Genome-wide association study of follicular lymphoma identifies a risk locus at 6p21.32. *Nature Genetics*, **2010**, 42, 661-4	36.3	137
131	Pancreatic cancer genetic epidemiology consortium. *Cancer Epidemiology Biomarkers and Prevention*, **2006**, 15, 704-10	4	116
130	Brief report: natural history of individuals with clinically recognized monoclonal B-cell lymphocytosis compared with patients with Rai 0 chronic lymphocytic leukemia. *Journal of Clinical Oncology*, **2009**, 27, 3959-63	2.2	109
129	Genome-wide meta-analysis identifies five new susceptibility loci for pancreatic cancer. *Nature Communications*, **2018**, 9, 556	17.4	103
128	Genome-wide association study identifies a novel susceptibility locus at 6p21.3 among familial CLL. *Blood*, **2011**, 117, 1911-6	2.2	102
127	Age at diagnosis and the utility of prognostic testing in patients with chronic lymphocytic leukemia. *Cancer*, **2010**, 116, 4777-87	6.4	91
126	Prevalence of CDKN2A mutations in pancreatic cancer patients: implications for genetic counseling. *European Journal of Human Genetics*, **2011**, 19, 472-8	5.3	88

125	Pathway analysis of genome-wide association study data highlights pancreatic development genes as susceptibility factors for pancreatic cancer. *Carcinogenesis*, **2012**, 33, 1384-90	4.6	85
124	Characterization of large structural genetic mosaicism in human autosomes. *American Journal of Human Genetics*, **2015**, 96, 487-97	11	77
123	Prevalence of germ-line mutations in cancer genes among pancreatic cancer patients with a positive family history. *Genetics in Medicine*, **2018**, 20, 119-127	8.1	74
122	Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL). *Leukemia and Lymphoma*, **2017**, 58, 1630-1639	1.9	71
121	Meta-analysis of genome-wide association studies discovers multiple loci for chronic lymphocytic leukemia. *Nature Communications*, **2016**, 7, 10933	17.4	70
120	Metformin Use and Survival of Patients With Pancreatic Cancer: A Cautionary Lesson. *Journal of Clinical Oncology*, **2016**, 34, 1898-904	2.2	60
119	Female chromosome X mosaicism is age-related and preferentially affects the inactivated X chromosome. *Nature Communications*, **2016**, 7, 11843	17.4	59
118	Risk of malignancy in first-degree relatives of patients with pancreatic carcinoma. *Cancer*, **2005**, 104, 388-94	6.4	59
117	Cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations and risk for pancreatic adenocarcinoma. *Cancer*, **2010**, 116, 203-9	6.4	58
116	Hodgkin transformation of chronic lymphocytic leukemia: Incidence, outcomes, and comparison to de novo Hodgkin lymphoma. *American Journal of Hematology*, **2015**, 90, 334-8	7.1	56
115	Renal complications in chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis: the Mayo Clinic experience. *Haematologica*, **2015**, 100, 1180-8	6.6	53
114	Prevalence and characteristics of central nervous system involvement by chronic lymphocytic leukemia. *Haematologica*, **2016**, 101, 458-65	6.6	51
113	New-onset diabetes in pancreatic cancer: a study in the primary care setting. *Pancreatology*, **2012**, 12, 156-61	3.8	49
112	Exposure to environmental chemicals and heavy metals, and risk of pancreatic cancer. *Cancer Causes and Control*, **2015**, 26, 1583-91	2.8	48
111	Hypogammaglobulinemia in newly diagnosed chronic lymphocytic leukemia: Natural history, clinical correlates, and outcomes. *Cancer*, **2015**, 121, 2883-91	6.4	47
110	Chronic lymphocytic leukemia in young (≤55 years) patients: a comprehensive analysis of prognostic factors and outcomes. *Haematologica*, **2014**, 99, 140-7	6.6	47
109	Pancreatic cancer: associations of inflammatory potential of diet, cigarette smoking and long-standing diabetes. *Carcinogenesis*, **2016**, 37, 481-90	4.6	46
108	International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia. *Blood*, **2020**, 135, 1859-1869	2.2	45

107	The chronic lymphocytic leukemia international prognostic index predicts time to first treatment in early CLL: Independent validation in a prospective cohort of early stage patients. *American Journal of Hematology*, **2016**, 91, 1090-1095	7.1	43
106	Validation of the CLL-IPI and comparison with the MDACC prognostic index in newly diagnosed patients. *Blood*, **2016**, 128, 2093-2095	2.2	42
105	Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia. *Journal of Experimental Medicine*, **2018**, 215, 681-697	16.6	41
104	Relationship between co-morbidities at diagnosis, survival and ultimate cause of death in patients with chronic lymphocytic leukaemia (CLL): a prospective cohort study. *British Journal of Haematology*, **2017**, 178, 394-402	4.5	37
103	Epstein-Barr Virus MicroRNAs are Expressed in Patients with Chronic Lymphocytic Leukemia and Correlate with Overall Survival. *EBioMedicine*, **2015**, 2, 572-82	8.8	34
102	Identification of recurrent truncated DDX3X mutations in chronic lymphocytic leukaemia. *British Journal of Haematology*, **2015**, 169, 445-8	4.5	31
101	Clinical characteristics and outcomes of Richter transformation: experience of 204 patients from a single center. *Haematologica*, **2020**, 105, 765-773	6.6	31
100	Pharmacovigilance during ibrutinib therapy for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in routine clinical practice. *Leukemia and Lymphoma*, **2017**, 58, 1376-1383	1.9	30
99	Rapid disease progression following discontinuation of ibrutinib in patients with chronic lymphocytic leukemia treated in routine clinical practice. *Leukemia and Lymphoma*, **2019**, 60, 2712-2719	1.9	28
98	Analysis of Heritability and Genetic Architecture of Pancreatic Cancer: A PanC4 Study. *Cancer Epidemiology Biomarkers and Prevention*, **2019**, 28, 1238-1245	4	27
97	Incidence of chronic lymphocytic leukemia and high-count monoclonal B-cell lymphocytosis using the 2008 guidelines. *Cancer*, **2014**, 120, 2000-5	6.4	27
96	Autoimmune cytopenias in patients with chronic lymphocytic leukaemia treated with ibrutinib in routine clinical practice at an academic medical centre. *British Journal of Haematology*, **2018**, 183, 421-427	4.5	25
95	Association of Common Susceptibility Variants of Pancreatic Cancer in Higher-Risk Patients: A PACGENE Study. *Cancer Epidemiology Biomarkers and Prevention*, **2016**, 25, 1185-91	4	22
94	The impact of dose modification and temporary interruption of ibrutinib on outcomes of chronic lymphocytic leukemia patients in routine clinical practice. *Cancer Medicine*, **2020**, 9, 3390-3399	4.8	19
93	Pancreatic cancer risk is modulated by inflammatory potential of diet and ABO genotype: a consortia-based evaluation and replication study. *Carcinogenesis*, **2018**, 39, 1056-1067	4.6	18
92	Impact of diabetes mellitus on clinical outcomes in patients undergoing surgical resection for pancreatic cancer: a retrospective, cohort study. *American Journal of Gastroenterology*, **2014**, 109, 1484-92	9.7	17
91	Developmental subtypes assessed by DNA methylation-iPLEX forecast the natural history of chronic lymphocytic leukemia. *Blood*, **2019**, 134, 688-698	2.2	16
90	Agnostic Pathway/Gene Set Analysis of Genome-Wide Association Data Identifies Associations for Pancreatic Cancer. *Journal of the National Cancer Institute*, **2019**, 111, 557-567	9.7	16

89	CD49d associates with nodal presentation and subsequent development of lymphadenopathy in patients with chronic lymphocytic leukaemia. *British Journal of Haematology*, **2017**, 178, 99-105	4.5	15
88	Association of polygenic risk score with the risk of chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis. *Blood*, **2018**, 131, 2541-2551	2.2	15
87	Effect of Germline Mutations in Homologous Recombination Repair Genes on Overall Survival of Patients with Pancreatic Adenocarcinoma. *Clinical Cancer Research*, **2020**, 26, 6505-6512	12.9	15
86	Variants associated with susceptibility to pancreatic cancer and melanoma do not reciprocally affect risk. *Cancer Epidemiology Biomarkers and Prevention*, **2014**, 23, 1121-4	4	14
85	Germline Rare Coding Variants and Risk of Pancreatic Cancer in Minority Populations. *Cancer Epidemiology Biomarkers and Prevention*, **2018**, 27, 1364-1370	4	13
84	Factors influencing receptivity to future screening options for pancreatic cancer in those with and without pancreatic cancer family history. *Hereditary Cancer in Clinical Practice*, **2012**, 10, 8	2.3	13
83	Do variants associated with susceptibility to pancreatic cancer and type 2 diabetes reciprocally affect risk?. *PLoS ONE*, **2015**, 10, e0117230	3.7	13
82	Zinc transporter genes and urological cancers: integrated analysis suggests a role for ZIP11 in bladder cancer. *Tumor Biology*, **2015**, 36, 7431-7	2.9	12
81	Comparison between the CLL-IPI and the Barcelona-Brno prognostic model: Analysis of 1299 newly diagnosed cases. *American Journal of Hematology*, **2018**, 93, E35-E37	7.1	12
80	Granulomatous interstitial nephritis secondary to chronic lymphocytic leukemia/small lymphocytic lymphoma. *Annals of Diagnostic Pathology*, **2015**, 19, 130-6	2.2	11
79	The role of 18F-FDG-PET in detecting Richter's transformation of chronic lymphocytic leukemia in patients receiving therapy with a B-cell receptor inhibitor. *Haematologica*, **2020**, 105, 2675-2678	6.6	11
78	Incidence and risk of tumor lysis syndrome in patients with relapsed chronic lymphocytic leukemia (CLL) treated with venetoclax in routine clinical practice. *Leukemia and Lymphoma*, **2020**, 61, 2383-2388	1.9	11
77	Relationship of blood monocytes with chronic lymphocytic leukemia aggressiveness and outcomes: a multi-institutional study. *American Journal of Hematology*, **2016**, 91, 687-91	7.1	11
76	IGH translocations in chronic lymphocytic leukemia: Clinicopathologic features and clinical outcomes. *American Journal of Hematology*, **2019**, 94, 338-345	7.1	11
75	KRAS, NRAS, and BRAF mutations are highly enriched in trisomy 12 chronic lymphocytic leukemia and are associated with shorter treatment-free survival. *Leukemia*, **2019**, 33, 2111-2115	10.7	10
74	Outcomes of a large cohort of individuals with clinically ascertained high-count monoclonal B-cell lymphocytosis. *Haematologica*, **2018**, 103, e237-e240	6.6	9
73	Analysis of racial variations in disease characteristics, treatment patterns, and outcomes of patients with chronic lymphocytic leukemia. *American Journal of Hematology*, **2016**, 91, 677-80	7.1	9
72	Immunoglobulin heavy chain variable region gene and prediction of time to first treatment in patients with chronic lymphocytic leukemia: Mutational load or mutational status? Analysis of 1003 cases. *American Journal of Hematology*, **2018**, 93, E216-E219	7.1	9

71	Should Researchers Offer Results to Family Members of Cancer Biobank Participants? A Mixed-Methods Study of Proband and Family Preferences. *AJOB Empirical Bioethics*, **2019**, 10, 1-22	3	9
70	Genetically Predicted Telomere Length is not Associated with Pancreatic Cancer Risk. *Cancer Epidemiology Biomarkers and Prevention*, **2017**, 26, 971-974	4	8
69	Renal insufficiency is an independent prognostic factor in patients with chronic lymphocytic leukemia. *Haematologica*, **2017**, 102, e22-e25	6.6	8
68	Validation of a biological score to predict response in chronic lymphocytic leukemia patients treated front-line with bendamustine and rituximab. *Leukemia*, **2018**, 32, 1869-1873	10.7	8
67	Receptivity and preferences of pancreatic cancer family members for participating in lifestyle programs to reduce cancer risk. *Hereditary Cancer in Clinical Practice*, **2013**, 11, 3	2.3	8
66	Liver dysfunction in chronic lymphocytic leukemia: Prevalence, outcomes, and pathological findings. *American Journal of Hematology*, **2017**, 92, 1362-1369	7.1	8
65	The Importance of Pharmacovigilance during Ibrutinib Therapy for Chronic Lymphocytic Leukemia (CLL) in Routine Clinical Practice. *Blood*, **2015**, 126, 717-717	2.2	7
64	Risk of serious infection among individuals with and without low count monoclonal B-cell lymphocytosis (MBL). *Leukemia*, **2021**, 35, 239-244	10.7	7
63	Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib: risk prediction, management, and clinical outcomes. *Annals of Hematology*, **2021**, 100, 143-155	3	7
62	Chronic lymphocytic leukemia cells from ibrutinib treated patients are sensitive to Axl receptor tyrosine kinase inhibitor therapy. *Oncotarget*, **2018**, 9, 37173-37184	3.3	7
61	Risk of Pancreatic Cancer Among Individuals With Pathogenic Variants in the ATM Gene. *JAMA Oncology*, **2021**, 7, 1664-1668	13.4	7
60	Tumor mutational load predicts time to first treatment in chronic lymphocytic leukemia (CLL) and monoclonal B-cell lymphocytosis beyond the CLL international prognostic index. *American Journal of Hematology*, **2020**, 95, 906-917	7.1	6
59	A laboratory-based scoring system predicts early treatment in Rai 0 chronic lymphocytic leukemia. *Haematologica*, **2020**, 105, 1613-1620	6.6	6
58	Pancreatic cancer and melanoma related perceptions and behaviors following disclosure of CDKN2A variant status as a research result. *Genetics in Medicine*, **2019**, 21, 2468-2477	8.1	5
57	Predictive value of the CLL-IPI in CLL patients receiving chemo-immunotherapy as first-line treatment. *European Journal of Haematology*, **2018**, 101, 703	3.8	5
56	Risk of Different Cancers Among First-degree Relatives of Pancreatic Cancer Patients: Influence of ProbandsRSusceptibility Gene Mutation Status. *Journal of the National Cancer Institute*, **2019**, 111, 264-271	9.7	5
55	Hodgkin Transformation Of Chronic Lymphocytic Leukemia (CLL): Mayo Clinic Experience. *Blood*, **2013**, 122, 1642-1642	2.2	5
54	Atrial Fibrillation in Patients with Chronic Lymphocytic Leukemia (CLL). *Blood*, **2015**, 126, 2950-2950	2.2	5

53	Addition of venetoclax at time of progression in ibrutinib-treated patients with chronic lymphocytic leukemia: Combination therapy to prevent ibrutinib flare. *American Journal of Hematology*, **2020**, 95, E57-E60	7.1	5
52	Disease Flare During Temporary Interruption of Ibrutinib Therapy in Patients with Chronic Lymphocytic Leukemia. *Oncologist*, **2020**, 25, 974-980	5.7	5
51	Genome-Wide Gene-Diabetes and Gene-Obesity Interaction Scan in 8,255 Cases and 11,900 Controls from PanScan and PanC4 Consortia. *Cancer Epidemiology Biomarkers and Prevention*, **2020**, 29, 1784-1791	4	4
50	Outcomes Of Chronic Lymphocytic Leukemia Patients With Richter Syndrome. *Blood*, **2013**, 122, 4179-4179	2.2	4
49	Humoral and cellular immune responses to recombinant herpes zoster vaccine in patients with chronic lymphocytic leukemia and monoclonal B cell lymphocytosis. *American Journal of Hematology*, **2021**, 97, 90	7.1	4
48	The CLL International Prognostic Index predicts outcomes in monoclonal B-cell lymphocytosis and Rai 0 CLL. *Blood*, **2021**, 138, 149-159	2.2	4
47	Natural history of monoclonal B-cell lymphocytosis among relatives in CLL families. *Blood*, **2021**, 137, 2046-2056	2.2	4
46	Psychological Impact of Learning CDKN2A Variant Status as a Genetic Research Result. *Public Health Genomics*, **2018**, 21, 154-163	1.9	4
45	Heritable Predisposition To Richter Syndrome In Patients With Chronic Lymphocytic Leukemia. *Blood*, **2013**, 122, 2867-2867	2.2	3
44	Prevalence of Low Count (LC) Monoclonal B Cell Lymphocytosis (MBL) and Serious Infections in a Population-Based Cohort of U.S. Adults Participating in a Large Bio-Repository. *Blood*, **2017**, 130, 831-831	2.2	3
43	Leukocyte Telomere Length and Its Interaction with Germline Variation in Telomere-Related Genes in Relation to Pancreatic Adenocarcinoma Risk. *Cancer Epidemiology Biomarkers and Prevention*, **2020**, 29, 1492-1500	4	2
42	Association of elevated serumfree light chains with chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis. *Blood Cancer Journal*, **2019**, 9, 59	7	2
41	BTK and/or PLCG2 Mutations in Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Ibrutinib: Characteristics and Outcomes at the Time of Progression. *Blood*, **2019**, 134, 3050-3050	2.2	2
40	Hypogammaglobulinemia In Patients With Previously Untreated Chronic Lymphocytic Leukemia: Clinical Correlates and Outcomes. *Blood*, **2013**, 122, 4178-4178	2.2	2
39	Delineation of clinical and biological factors associated with cutaneous squamous cell carcinoma among patients with chronic lymphocytic leukemia. *Journal of the American Academy of Dermatology*, **2020**, 83, 1581-1589	4.5	2
38	Mendelian Randomization Analysis of n-6 Polyunsaturated Fatty Acid Levels and Pancreatic Cancer Risk. *Cancer Epidemiology Biomarkers and Prevention*, **2020**, 29, 2735-2739	4	2
37	Smoking Modifies Pancreatic Cancer Risk Loci on 2q21.3. *Cancer Research*, **2021**, 81, 3134-3143	10.1	2
36	Genome-Wide Association Study Data Reveal Genetic Susceptibility to Chronic Inflammatory Intestinal Diseases and Pancreatic Ductal Adenocarcinoma Risk. *Cancer Research*, **2020**, 80, 4004-4013	10.1	1

35	Immunogenicity of a Recombinant Herpes Zoster Vaccine in Patients with Chronic Lymphocytic Leukemia. *Blood*, **2020**, 136, 49-50	2.2	1
34	Chronic lymphocytic leukemia (CLL) with Reed-Sternberg-like cells vs Classic Hodgkin lymphoma transformation of CLL: does this distinction matter?. *Blood Cancer Journal*, **2022**, 12, 18	7	1
33	Venetoclax Has Modest Efficacy in the Treatment of Patients with Relapsed T-Cell Prolymphocytic Leukemia. *Blood*, **2020**, 136, 39-40	2.2	1
32	Serum B-cell maturation antigen as a prognostic marker for untreated chronic lymphocytic leukemia.. *Journal of Clinical Oncology*, **2019**, 37, 7525-7525	2.2	1
31	A risk prediction tool for individuals with a family history of breast, ovarian, or pancreatic cancer: BRCAPANCPRO. *British Journal of Cancer*, **2021**, 125, 1712-1717	8.7	1
30	Venetoclax treatment of patients with relapsed T-cell prolymphocytic leukemia. *Blood Cancer Journal*, **2021**, 11, 47	7	1
29	The prognostic significance of del6q23 in chronic lymphocytic leukemia. *American Journal of Hematology*, **2021**, 96, E203-E206	7.1	1
28	Polygenic risk score and risk of monoclonal B-cell lymphocytosis in caucasians and risk of chronic lymphocytic leukemia (CLL) in African Americans. *Leukemia*, **2021**,	10.7	1
27	Shorter Treatment-Naïve Leukocyte Telomere Length is Associated with Poorer Overall Survival of Patients with Pancreatic Ductal Adenocarcinoma. *Cancer Epidemiology Biomarkers and Prevention*, **2021**, 30, 210-216	4	0
26	A rare germline CDKN2A variant (47T>G; p16-L16R) predisposes carriers to pancreatic cancer by reducing cell cycle inhibition. *Journal of Biological Chemistry*, **2021**, 296, 100634	5.4	0
25	Cause of death in patients with newly diagnosed chronic lymphocytic leukemia (CLL) stratified by the CLL-International Prognostic Index. *Blood Cancer Journal*, **2021**, 11, 140	7	0
24	Polygenic Risk Score and Risk of Chronic Lymphocytic Leukemia, Monoclonal B-Cell Lymphocytosis (MBL), and MBL Subtypes. *Blood*, **2020**, 136, 35-36	2.2	
23	Clinical Characteristics and Outcomes of Newly Diagnosed Patients with Chronic Lymphocytic Leukemia Who Are 80 Years of Age or Older. *Blood*, **2020**, 136, 26-27	2.2	
22	Impact of Deletion6q23 Identified By FISH in Patients with Chronic Lymphocytic Leukemia. *Blood*, **2020**, 136, 12-13	2.2	
21	Telomere Length Is Associated with Epigenetic Programming in CLL and Is a Superior Predictor of Clinical Outcome with the Ability to Bifurcate Patients with the Same CLL-IPI Score. *Blood*, **2018**, 132, 1833-1833	2.2	
20	Clonal Hematopoiesis of Indeterminate Potential (CHIP) and Chronic Lymphocytic Leukemia (CLL) Driver Genes: Risk of CLL and Monoclonal B-Cell Lymphocytosis (MBL). *Blood*, **2018**, 132, 3116-3116	2.2	
19	Clinical Characteristics and Outcomes of Chronic Lymphocytic Leukemia Patients with Richter Transformation. *Blood*, **2018**, 132, 1857-1857	2.2	
18	A Laboratory Based Scoring System Predicts Early Treatment in Rai 0/Binet a CLL. *Blood*, **2018**, 132, 4399-4399	2.2	

List of Publications

17	Risk Model for Overall Survival for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Validated for Patients on Ibrutinib, Idelalisib, Venetoclax, or Chemoimmunotherapy. *Blood*, **2018**, 132, 4394-4394	2.2
16	Association between the Risk of Low/High-Count Monoclonal B-Cell Lymphocytosis (MBL) and the Chronic Lymphocytic Leukemia (CLL) Polygenic Risk Score (PRS). *Blood*, **2018**, 132, 5538-5538	2.2
15	Developmental DNA Methylation Subtype Predicts Progression to Treatment and Survival in High-Count Monoclonal B Lymphocytosis. *Blood*, **2019**, 134, 3022-3022	2.2
14	Tumor Mutational Load and Germline Polygenic Risk Score Predicts Time-to-First Treatment in Chronic Lymphocytic Leukemia (CLL) and High-Count Monoclonal B Cell Lymphocytosis (MBL). *Blood*, **2019**, 134, 852-852	2.2
13	The Role of Imaging in Predicting Time to First Treatment and Overall Survival in Individuals with CLL-like High Count Monoclonal B-Cell Lymphocytosis. *Blood*, **2019**, 134, 3037-3037	2.2
12	Accuracy of Smoking Status Reporting: Proxy Information in a Rapidly Fatal Cancer Setting. *Mayo Clinic Proceedings Innovations, Quality & Outcomes*, **2020**, 4, 801-809	3.1
11	Correlation Between Peripheral Blood Counts and Extent of Bone Marrow Infiltration in Chronic Lymphocytic Leukemia. *Blood*, **2015**, 126, 2926-2926	2.2
10	Mutations in Driver Genes and Changes in Clonal Dynamics Are Associated with Shorter Time to Treatment in MBL Cases. *Blood*, **2015**, 126, 5264-5264	2.2
9	Infectious Complications Among Individuals with Monoclonal B-Cell Lymphocytosis (MBL): A Prospective Case-Control Study of Newly Diagnosed Patients,. *Blood*, **2011**, 118, 3903-3903	2.2
8	Prevalence of MBL Increases Over Time In Relatives of CLL Families,. *Blood*, **2011**, 118, 3881-3881	2.2
7	Alemtuzumab Use and Survival After Reduced Intensity Allogeneic Stem Cell Transplantation in High-Risk Chronic Lymphocytic Leukemia (CLL),. *Blood*, **2011**, 118, 4152-4152	2.2
6	In Patients Newly Diagnosed with Chronic Lymphocytic Leukemia the Absolute Monocyte Count At Presentation Is Directly Associated with Disease Progression Independently From Rai Staging or Cytogenetics. *Blood*, **2011**, 118, 2835-2835	2.2
5	The Prevalence of Serious Infectious Complications in a Cohort of Non-Referred Patients with Newly Diagnosed Chronic Lymphocytic Leukemia (CLL) Compared to Controls: Results of a Cohort Study. *Blood*, **2011**, 118, 4610-4610	2.2
4	Clonal Evolution In Patients With Previously Untreated Chronic Lymphocytic Leukemia. *Blood*, **2013**, 122, 1643-1643	2.2
3	Chronic Graft Vs Host Disease Is The Strongest Predictor Of Outcome After Reduced Intensity Conditioning Stem Cell Transplantation In Chronic Lymphocytic Leukemia and Is Associated With Pretransplant B Cell Characteristics. *Blood*, **2013**, 122, 3375-3375	2.2
2	Risk factors for hypogammaglobulinemia in chronic lymphocytic leukemia patients treated with anti-CD20 monoclonal antibody-based therapies. *Journal of Hematopathology*, **2020**, 13, 221-229	0.4
1	Bayesian copy number detection and association in large-scale studies. *BMC Cancer*, **2020**, 20, 856	4.8